Anti-inflammatory effects of medications used for viral infection-induced respiratory diseases

Medicine and Dentistry

• Respiratory Disease 100%
• Virus Infection 83%
• Medication 50%
• Mediator 33%
• Mucin 33%
• Antiinflammatory Activity 33%
• Chronic Obstructive Pulmonary Disease 33%
• Asthma 33%
• Influenza Virus 33%
• Bronchiectasis 33%
• Diffuse Panbronchiolitis 33%
• Pulmonary Fibrosis 16%
• Serositis 16%
• In Vitro 16%
• Cytokine 16%
• Agonist 16%
• Tumor Necrosis Factor 16%
• Interleukin 6 16%
• Corticosteroid 16%
• Inflammatory Mediator 16%
• Bronchitis 16%
• Pneumonia 16%
• Mortality Rate 16%
• Interleukin 1 16%
• Epithelial Cell 16%
• Mitogen-Activated Protein Kinase 16%
• Respiratory Tract Allergy 16%
• Inflammatory Cell 16%
• Mucus Secretion 16%
• Antivirus Agent 16%
• Interleukin 8 16%
• Macrolide 16%
• Injury 16%
• Development 16%
• Human Respiratory Syncytial Virus 16%
• Toll Like Receptor 16%
• Granulocyte Macrophage Colony Stimulating Factor 16%
• Immunoglobulin Enhancer Binding Protein 16%
• Rhinovirus 16%
• Airway Remodeling 16%
• Kampo 16%
• Muscarinic Antagonist 16%
• Mucolytic Agent 16%
• Symptom 16%
• COVID-19 16%
• Severe Acute Respiratory Syndrome Coronavirus 2 16%
• Cells 16%
• Quality of Life 16%
• Lung 16%
• Inpatient 16%
• T Cell 16%
• Virus 16%
• Coronavirinae 16%